Skip to Content
Merck

Acute rhabdomyolysis associated with ofloxacin/levofloxacin therapy.

The Annals of pharmacotherapy (2004-11-25)
Shu-Hwa Hsiao, Chia-Ming Chang, Chao-Jung Tsao, Yu-Yun J Lee, May-Ying Hsu, Ta-Jen Wu
ABSTRACT

To report a case of ofloxacin/levofloxacin-induced rhabdomyolysis and to compare other reported cases from the literature. A 19-year-old male patient developed ofloxacin/levofloxacin-induced rhabdomyolysis during admission for periorbital cellulitis. Symptoms of myalgia, weakness, and swelling of the arms developed after 3 days of treatment with ofloxacin 800 mg/day. Laboratory analysis confirmed the presence of urine myoglobin (381.2 microg/L) and a marked increase in serum myoglobin (590.8 microg/L), along with marked elevations in serum creatine kinase (up to 16 546 IU/L). In addition to ruling out other possible etiologic factors one by one, we assessed the probability of ofloxacin/levofloxacin-induced rhabdomyolysis by observing the close time relationship between drug administration and the development of symptoms/signs, as well as the close time relationship between drug withdrawal and the disappearance of symptoms/signs. An objective causality assessment by use of the Naranjo probability scale revealed that the adverse drug reaction was probable. Although ofloxacin/levofloxacin-induced rhabdomyolysis appears to be rare, patients with muscle pain, swelling, or weakness during therapy should be closely monitored for this adverse effect.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ofloxacin, fluoroquinolone antibiotic
Supelco
Ofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Ofloxacin, VETRANAL®, analytical standard
Ofloxacin, European Pharmacopoeia (EP) Reference Standard
USP
Ofloxacin, United States Pharmacopeia (USP) Reference Standard